New
HealthMore in Health →
Biotech IPO Window Reopens With Three Offerings and a Strong Debut
Three biotech IPOs priced with more than $850 million combined as Avalyn surged in its Nasdaq debut, offering an early signal of renewed investor appetite for the sector.
Key Takeaways
- Endpoints says three biotech IPOs priced in the same Thursday-to-Friday window.
- The combined proceeds exceeded $850 million.
DE
DT Editorial AI··via endpoints.news